Real-world effectiveness of antipsychotic medication in relapse prevention after cannabis-induced psychosis

dc.contributor.authorMustonen, Antti
dc.contributor.authorTaipale, Heidi
dc.contributor.authorDenissoff, Alexander
dc.contributor.authorEllilä, Venla
dc.contributor.authorDi Forti, Marta
dc.contributor.authorTanskanen, Antti
dc.contributor.authorMittendorfer-Rutz, Ellenor
dc.contributor.authorTiihonen, Jari
dc.contributor.authorNiemelä, Solja
dc.contributor.organizationfi=psykiatria|en=Psychiatry|
dc.contributor.organizationfi=tyks, vsshp|en=tyks, varha|
dc.contributor.organization-code1.2.246.10.2458963.20.16217176722
dc.contributor.organization-code2607316
dc.converis.publication-id498563813
dc.converis.urlhttps://research.utu.fi/converis/portal/Publication/498563813
dc.date.accessioned2025-08-28T03:39:18Z
dc.date.available2025-08-28T03:39:18Z
dc.description.abstract<p><b>Background </b>Cannabis use is linked to treatment non-adherence and relapses in psychotic disorders. Antipsychotic medication is effective for relapse prevention in primary psychoses, but its effectiveness after cannabis-induced psychosis (CIP) remains unclear.<br></p><p><b>Aims </b>To examine the effectiveness of antipsychotic medication for relapse prevention following the first clinically diagnosed CIP.<br></p><p><b>Method </b>A cohort of 1772 patients (84.1% men) with incident CIP was identified from the Swedish National Patient and Micro Data for Analyses of Social Insurance registers. The primary outcome was hospitalisation due to any psychotic episode. Drug use data were collected from the Prescribed Drug Register and modelled into drug use periods using the PRE2DUP method. A within-individual Cox regression model was used to study the risk of outcomes during the use of different oral or long-acting injectable (LAI) antipsychotics compared with non-use.<br></p><p><b>Results </b>The mean age at first diagnosis was 26.6 years (s.d. = 8.3). Of the cohort, 1343 (75.8%) used antipsychotics and 914 (51.3%) experienced psychosis hospitalisation during the follow-up. Any antipsychotic use was associated with a decreased risk of psychosis hospitalisation (adjusted hazard ratio (aHR) 0.75; 95% CI 0.67-0.84). Specific antipsychotics associated with decreased risk included aripiprazole LAI (aHR 0.27; 95% CI 0.14-0.51), olanzapine LAI (aHR 0.28; 95% CI 0.15-0.53), clozapine (aHR 0.55; 95% CI 0.34-0.90), oral aripiprazole (aHR 0.64; 95% CI 0.45-0.91), antipsychotic polytherapy (aHR 0.74; 95% CI 0.63-0.87) and oral olanzapine (aHR 0.81; 95% CI 0.69-0.94).<br></p><p><b>Conclusions </b>In particular, LAIs, clozapine and oral aripiprazole were associated with a decreased risk of psychosis relapse following CIP. Prescribers should consider using more LAIs for better treatment outcomes after CIP.<br></p>
dc.identifier.eissn1472-1465
dc.identifier.jour-issn0007-1250
dc.identifier.olddbid210958
dc.identifier.oldhandle10024/193985
dc.identifier.urihttps://www.utupub.fi/handle/11111/56735
dc.identifier.urlhttps://doi.org/10.1192/bjp.2025.72
dc.identifier.urnURN:NBN:fi-fe2025082790715
dc.language.isoen
dc.okm.affiliatedauthorDenissoff, Alexander
dc.okm.affiliatedauthorEllilä, Venla
dc.okm.affiliatedauthorNiemelä, Solja
dc.okm.affiliatedauthorDataimport, tyks, vsshp
dc.okm.discipline3124 Neurology and psychiatryen_GB
dc.okm.discipline3124 Neurologia ja psykiatriafi_FI
dc.okm.internationalcopublicationinternational co-publication
dc.okm.internationalityInternational publication
dc.okm.typeA1 ScientificArticle
dc.publisherCAMBRIDGE UNIV PRESS
dc.publisher.countryUnited Kingdomen_GB
dc.publisher.countryBritanniafi_FI
dc.publisher.country-codeGB
dc.publisher.placeCAMBRIDGE
dc.relation.doi10.1192/bjp.2025.72
dc.relation.ispartofjournalBritish Journal of Psychiatry
dc.source.identifierhttps://www.utupub.fi/handle/10024/193985
dc.titleReal-world effectiveness of antipsychotic medication in relapse prevention after cannabis-induced psychosis
dc.year.issued2025

Tiedostot

Näytetään 1 - 1 / 1
Ladataan...
Name:
real-world-effectiveness-of-antipsychotic-medication-in-relapse-prevention-after-cannabis-induced-psychosis.pdf
Size:
429.17 KB
Format:
Adobe Portable Document Format